CO2024001388A2 - Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2 - Google Patents

Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2

Info

Publication number
CO2024001388A2
CO2024001388A2 CONC2024/0001388A CO2024001388A CO2024001388A2 CO 2024001388 A2 CO2024001388 A2 CO 2024001388A2 CO 2024001388 A CO2024001388 A CO 2024001388A CO 2024001388 A2 CO2024001388 A2 CO 2024001388A2
Authority
CO
Colombia
Prior art keywords
antibodies
binding fragments
cov
sars
antigen binding
Prior art date
Application number
CONC2024/0001388A
Other languages
English (en)
Inventor
George D Yancopoulos
Alina Baum
Christos Kyratsous
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2024001388A2 publication Critical patent/CO2024001388A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona anticuerpos y fragmentos de unión al antígeno de estos que se unen específicamente a una proteína de la espícula del coronavirus y métodos para usar dichos anticuerpos y fragmentos para tratar o prevenir infecciones virales (por ejemplo, infecciones por coronavirus).
CONC2024/0001388A 2021-07-14 2024-02-09 Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2 CO2024001388A2 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163221846P 2021-07-14 2021-07-14
US202163245020P 2021-09-16 2021-09-16
US202163286514P 2021-12-06 2021-12-06
US202163289126P 2021-12-13 2021-12-13
US202163289419P 2021-12-14 2021-12-14
US202163291328P 2021-12-17 2021-12-17
US202263301002P 2022-01-19 2022-01-19
US202263306909P 2022-02-04 2022-02-04
US202263354632P 2022-06-22 2022-06-22
PCT/US2022/036950 WO2023287875A1 (en) 2021-07-14 2022-07-13 Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Publications (1)

Publication Number Publication Date
CO2024001388A2 true CO2024001388A2 (es) 2024-02-15

Family

ID=82838954

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0001388A CO2024001388A2 (es) 2021-07-14 2024-02-09 Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2

Country Status (13)

Country Link
US (1) US20230125469A1 (es)
EP (1) EP4370210A1 (es)
JP (1) JP2024527607A (es)
KR (1) KR20240046322A (es)
AU (1) AU2022311906A1 (es)
BR (1) BR112024000744A2 (es)
CA (1) CA3225575A1 (es)
CL (1) CL2024000091A1 (es)
CO (1) CO2024001388A2 (es)
IL (1) IL310012A (es)
MX (1) MX2024000563A (es)
TW (1) TW202321292A (es)
WO (1) WO2023287875A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309072A1 (en) 2023-02-28 2024-09-19 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof
WO2024182451A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US7737725B1 (en) 2008-04-04 2010-06-15 Xilinx, Inc. Device control register for a processor block
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
KR20200115576A (ko) 2018-01-26 2020-10-07 리제너론 파아마슈티컬스, 인크. 항-tmprss2 항체 및 항원-결합 단편
BR112022017986A2 (pt) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticorpos anticoronavírus e métodos de uso
SG11202103404PA (en) * 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021203053A1 (en) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
MX2022013886A (es) * 2020-05-08 2022-11-30 Vir Biotechnology Inc Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
AR122111A1 (es) * 2020-05-17 2022-08-17 Astrazeneca Uk Ltd ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS
EP4157455A1 (en) * 2020-05-29 2023-04-05 Universität zu Köln Neutralizing antibodies against sars-related coronavirus
WO2021245184A1 (en) * 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2022162587A1 (en) * 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Also Published As

Publication number Publication date
US20230125469A1 (en) 2023-04-27
BR112024000744A2 (pt) 2024-04-30
JP2024527607A (ja) 2024-07-25
TW202321292A (zh) 2023-06-01
KR20240046322A (ko) 2024-04-08
WO2023287875A1 (en) 2023-01-19
AU2022311906A1 (en) 2024-01-25
IL310012A (en) 2024-03-01
MX2024000563A (es) 2024-04-10
EP4370210A1 (en) 2024-05-22
CL2024000091A1 (es) 2024-08-09
CA3225575A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CO2024001388A2 (es) Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2
MD3638698T2 (ro) Anticorpi anti-TMPRSS2 și fragmente de legare al antigenului
UY39118A (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CO7061039A2 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
MX2022014598A (es) Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CL2022003390A1 (es) Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.
ECSP14020504A (es) Anticuerpos contra la metaloproteinasa de la matriz 9
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
MX2021006930A (es) Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
DOP2023000039A (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
AR119296A1 (es) Anticuerpos de glicoproteína anti proteína s de sars cov-2- y fragmentos de unión de antígenos
BR112021024401A2 (pt) Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
BR112022005787A2 (pt) Proteínas de ligação a antígeno
AR107012A1 (es) ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A ErbB3 Y EL USO DEL MISMO
AR111185A1 (es) Anticuerpos que se unen al receptor 2 activado por proteasas (par2) y usos de los mismos en el tratamiento del dolor nociceptivo neuropático y de tipo mixto
EA201992186A1 (ru) Антитела к par2 и пути их применения